Pyxus International reports strong financial performance for 2022 Q3

Feb.16.2023
Pyxus International reports strong financial performance for 2022 Q3
Pyxus International reports Q3 2022 revenue of $655.6m and decreased net losses, driven by strong global performance and improved financial flexibility.

Pyxus International has released their financial performance report for the period ending on December 31, 2022.


For the three months ending on December 31st, 2022:


Sales and other operating revenues increased by $226.7 million, up 52.9%, reaching $655.6 million.


Operating profit increased by $11.4 million, reaching $41.6 million.


The net loss belonging to Pyxus International has improved, decreasing from $27.8 million to $2.3 million.


Pieter Sikkel, President and CEO of Pyxus, has expressed his satisfaction with the company's third-quarter results. Despite the challenges posed by La Niña and inflationary pressure, as well as the unpredictability of last year's crop cycle, the increase in operating profit indicates a strong performance on a global scale. The results demonstrate progress made by the company across multiple areas compared to the previous year, which could not have been achieved without the dedication and contributions of its employees.


We successfully utilized our global business network to address the current tobacco supply shortage and achieved our purchasing goals for the 2023 fiscal year. In addition to the normalization of our North and South American shipping plans and increased freight from Asia, the company achieved a year-over-year sales and other operating revenue growth of over 50%. This growth, along with a higher utilization of our securitization plan, resulted in over $100 million in increased operating cash flow for the third quarter compared to the same period last year. Some of these funds were strategically used to fully pay off the outstanding debt on our ABL credit facility, providing the company with greater financial flexibility and more funding support as we approach the next purchasing cycle.


Due to the normalization of shipping schedules, we anticipate that the third quarter will be the biggest sales quarter of the fiscal year. Based on our expectations for continued improvement, we have revised our projected sales for the 2023 fiscal year to be between $1.85 billion and $2 billion, with adjusted EBITDA expectations of $140 million to $155 million.


Pyxus International is a global tobacco company headquartered in North Carolina, United States. The company specializes in procuring, processing, and selling tobacco, and owns multiple tobacco brands. Additionally, Pyxus International also has ventures in other industries such as agriculture and food.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Poll Shows Britons Favor Regulation Over Bans on Nicotine Pouches
Poll Shows Britons Favor Regulation Over Bans on Nicotine Pouches
A new poll commissioned by We Vape UK reveals that most Britons favor regulation — not prohibition — of nicotine pouches. The survey shows broad public support for harm-reduction policies and frustration with weak government regulation, contrasting sharply with Ireland’s recent decision to ban disposable vapes and impose strict limits on nicotine products.
Nov.25 by 2FIRSTS.ai
2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts observed at Stockholm Arlanda Airport that British American Tobacco’s VELO positions the airport environment as a core marketing scenario, deploying large-format LED displays, a full flavour matrix, and clear nicotine-strength segmentation. The brand also features an instructional “How to Use VELO” section and multi-pack sales strategy, showcasing its systematic merchandising capabilities in the Nordic travel-retail channel.
Nov.19 by 2FIRSTS.ai
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G has launched the limited-edition “lil hybrid 3.0 Misty Rose Edition” heated tobacco device in South Korea, betting on year-end consumer demand with a gradient rose-colored design. The release is capped at 20,000 units and is available through both online and offline channels, with an official retail price of 78,000 won (approximately USD 53).
Nov.20 by 2FIRSTS.ai
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
California-based vape manufacturer Schwartz E-Liquid (USA Vape Lab) has sued the U.S. Food and Drug Administration (FDA) in federal court, alleging the agency unlawfully failed to issue a decision on its premarket application for flavored e-cigarette products for more than five years. The company is seeking a court order compelling the FDA to act within 90 days.
Nov.26 by 2FIRSTS.ai
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
This opinion piece, submitted by Samrat Chowdhery to 2Firsts, challenges the logic of tobacco price elasticity. It argues that high taxes often harm vulnerable populations and fuel illicit markets rather than reducing smoking.
Oct.21
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai